12,372 trials
Psoriatic Arthritis
Primary: Percentage of Participants With Active Psoriatic Arthritis (PsA) Achieving an American College of Rheumatology Response 20 (ACR20) at Week 16 — 59.5; 55.5; 62.6; 27.4…
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough (Pre-bronchodilator) Forced Expiratory Volume in 1 Second (FEV1) on Treatment Day 169 — -0.022; 0.131 Liters — p=<0.001
Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis
Primary: Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T Cell, B Cell, Natural Killer Cell (TBNK) — 235.9; -18.8; -48.2; -65.9 cells per cubic millimeter…
Pneumonia
Primary: Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population — 103; 95 Participants
Hepatitis B · Pertussis
Primary: Percentage of Participants Responding to Hepatitis B Surface Antigen (HBsAg) — 70.16; 82.01; 65.75; 83.68 Percentage of Participants
Progressive IgA Nephropathy · Proteinuria
Primary: Number of Subjects With a Complete or Partial Response to Treatment — 8 Participants
Spinal Cord Injury · Dyslipidemia
Primary: Triglyceride Concentration (Percent Change From Baseline) — -40; -2 percent change from baseline
Psoriasis
Primary: Participants With Psoriasis Area and Severity Index (PASI) 75 Response After 12 Weeks of Treatment — 64; 1 participants — p=< 0.0001
Extraocular Retinoblastoma
Primary: Event-free Survival (EFS) — 88; 83; 28 Probability
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Primary: Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL — 0.99; 1.21; 1.09; 1.17 Exacerbations per year — p=0.0638
Osteoarthritis, Hip · Osteoarthritis, Knee
Primary: Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24 — -2.24; -2.70; -2.85 units on a scale — p=0.0088
Rheumatoid Arthritis
Primary: ACR-20 - 20% Improvement According to American College of Rheumatology Criteria — 232; 233 Participants
Fibromyalgia
Primary: Number of Participants With a 30% Improvement in Pain or 20% Improvement in Function — 24; 13; 21; 15 Participants
Major Depressive Disorder
Primary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score to Week 8 — -12.37; -15.03; -15.45 Scores on a scale — p=0.0080
Narcolepsy · Obstructive Sleep Apnea
Primary: Change in Epworth Sleepiness Scale (ESS) Score — 1.6; 5.3 points on a scale